Description
Raloxifeneisaselectiveestrogenreceptormodulator(SERM)thatexhibitsagoNISTactivityinboneandantagonistactivityinuterineandbreasttissues.Raloxifeneisclinicallyusedtopreventosteoporosisinpost-menopausalwomenandtotreatER+breastcancer.Thiscompoundexhibitsanti-osteoporotic,anti-parasitic,neuromodulatory,andanticancerchemotherapeuticactivities.Raloxifenedecreasesfractureriskandenhancesbonestrengthinclinicalsettings.Invitroandinvivo,raloxifeneinhibitsgrowthofLeishmaniaandparasiticburden.Additionally,raloxifeneincreasesuptakeofglutamateandexpressionofGLT-1inastrocytes.Inanimalmodelsofbreastcancer,thiscompounddecreasesexpressionofEGFR,vasculardensity,andtumorgrowth.
References
KarkiP,WebbA,ZerguineA,etal.Mechanismofraloxifene-inducedupregulationofglutamatetransportersinratprimaryastrocytes.Glia.2014Aug;62(8):1270-83.PMID:24782323.
ReimãoJQ,MiguelDC,TaniwakiNN,etal.Antileishmanialactivityoftheestrogenreceptormodulatorraloxifene.PLoSNeglTropDis.2014May8;8(5):e2842.PMID:24810565.
GallantMA,BrownDM,HammondM,etal.Bonecell-independentbenefitsofraloxifeneontheskeleton:anovelmechanismforimprovingbonematerialproperties.Bone.2014Apr;61:191-200.PMID:24468719.
TaurinS,AllenKM,ScandlynMJ,etal.Raloxifenereducestriple-negativebreastcancertumorgrowthanddecreasesEGFRexpression.IntJOncol.2013Sep;43(3):785-92.PMID:23842642.
GizzoS,SaccardiC,PatrelliTS,etal.Updateonraloxifene:mechanismofaction,clinicalefficacy,adverseeffects,andcontraindications.ObstetGynecolSurv.2013Jun;68(6):467-81.PMID:23942473.